

(FILE 'HOME' ENTERED AT 13:34:41 ON 05 SEP 2006)

FILE 'USPATFULL' ENTERED AT 13:34:51 ON 05 SEP 2006

```
L1      71 S CONJUGATED LINOLEIC ACID/TI
L2      268 S CONJUGATED LINOLEIC ACID/CLM
L3      146 S CONJUGATED LINOLEIC ACID/AB
L4      58 S L1 AND L2 AND L3
L5      34 S L4 AND (TABLET OR CAPSULE)
L6      2 S L5 AND PHOSPHOLIPID/CLM
L7      23 S L5 AND PHOSPHOLIPID
L8      21 S L7 NOT L6
L9      0 S L8 AND PHOSPHOLIPID/AB
L10     39 S CONJUGATED LINOLEIC ACID (2S) (PHOSPHOLIPID)
L11     1 S L10 AND L8
```

=> save all teamp

TEAMP IS NOT A VALID SAVED NAME

Enter the name you wish to use for the saved query,
answer set, or L-number list. The name must:

1. Begin with a letter,
2. Have 1-12 characters,
3. Contain only letters (A-Z) and numbers (0-9),
4. End with /Q for a query (search profile,
structure, or screen set), /A for an answer
set, or /L for an L-number list.
5. Not already be in use as a saved name,
6. Not be END, SAV, SAVE, SAVED
7. Not have the form of an L-number (Lnnn).

ENTER NAME OR (END):end

=> save all temp

ENTER NAME OR (END):l10721231a/1

L# LIST L1-L11 HAS BEEN SAVED AS 'L10721231A/L'

75% OF LIMIT FOR SAVED L# LISTS REACHED

=>

L11 ANSWER 1 OF 1 USPATFULL on STN

TI Agent for increasing brown fat, comprising **conjugated linoleic acid** as active ingredient

AB There is provided an agent for increasing brown fat, comprising a **conjugated linoleic acid** as an active ingredient.

DETD [0011] Forms of the **conjugated linoleic acid** usable herein include fatty acids, mono-, di-, or triglycerides, sodium salts, potassium salts, calcium salts, **phospholipids**, and lysophospholipids, and a mixture of two or more of them. Among them, fatty acids, triglycerides, **phospholipids**, and calcium salts are preferred. Further, derivatives of **conjugated linoleic acids**, for example, ascorbic acid derivatives and mitomycin C derivatives, may also be used.

DETD . . . starch, dextrin, gum arabic or the like). The agent for increasing brown fat may be used in the form of **tablets**, **capsules**, or liquids.

CLM What is claimed is:

1. An agent for increasing brown fat, comprising a **conjugated linoleic acid** as an active ingredient.

2. The agent for increasing brown fat according to claim 1, wherein the **conjugated linoleic acid** is selected from the group consisting of 9,11-octadecadienoic acid, 10,12-octadecadienoic acid, and a mixture of said compounds.

3. The agent for increasing brown fat according to claim 1, wherein said **conjugated linoleic acid** is used in the form of a fatty acid, a sodium salt, a potassium salt, a calcium salt, a triglyceride, . . .

4. A food or a feed having a capability of increasing brown fat, said food or feed comprising the **conjugated linoleic acid** according to claim 1.

5. The food or feed according to claim 4, which is in the form of a **conjugated linoleic acid**-containing fat-and-oil product.

ACCESSION NUMBER: 2002:26926 USPATFULL

TITLE: Agent for increasing brown fat, comprising **conjugated linoleic acid** as active ingredient

INVENTOR(S): Sugano, Michihiro, Kumamoto-shi, JAPAN
Sakuno, Masanobu, Miyazaki-shi, JAPAN
Koba, Kazunori, Nagasaki-shi, JAPAN
Okuyama, Hitoshi, Tokyo-To, JAPAN
Kasai, Masaaki, Nagoya-shi, JAPAN
Iwata, Toshio, Tokyo-To, JAPAN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002015771	A1	20020207
	US 6451336	B2	20020917
APPLICATION INFO.:	US 2000-560902	A1	20000428 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1999-122794	19990428
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Foley & Lardner, Washington Harbour, 3000 K Street NW, Suite 500, Washington, DC, 20007-5109	
NUMBER OF CLAIMS:	7	

EXEMPLARY CLAIM: 1

LINE COUNT: 231

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 40 OF 58 USPATFULL on STN
 AN 2002:22529 USPATFULL
 TI **Conjugated linoleic acid powder**
 IN Fimreite, Duane, Chicago, IL, UNITED STATES
 PA Natural ASA, Sandvika, NORWAY, N-1337 (U.S. corporation)
 PI US 2002013365 A1 20020131
 US 6756405 B2 20040629
 AI US 2001-836788 A1 20010417 (9)
 PRAI US 2000-198487P 20000418 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1330
 INCL INCLM: 514/552.000
 INCLS: 514/560.000; 514/547.000
 NCL NCLM: 514/560.000; 514/552.000
 NCLS: 424/439.000; 514/546.000; 514/549.000; 514/558.000; 514/547.000
 IC [7]
 ICM A61K031-232
 ICS A61K031-202
 IPCI A61K0031-232 [ICM,7]; A61K0031-21 [ICM,7,C*]; A61K0031-202
 [ICS,7]; A61K0031-185 [ICS,7,C*]
 IPCI-2 A61K0031-22 [ICM,7]; A61K0031-20 [ICS,7]; A61K0031-185
 [ICS,7,C*]; A61K0007-00 [ICS,7]; A61K0031-231 [ICS,7];
 A61K0031-21 [ICS,7,C*]; A61K0035-78 [ICS,7]
 IPCR A23D0009-02 [I,C*]; A23D0009-05 [I,A]; A23K0001-16 [I,A];
 A23K0001-16 [I,C*]; A23K0001-18 [I,A]; A23K0001-18 [I,C*];
 A23L0001-30 [I,A]; A23L0001-30 [I,C*]; A61K0031-185 [I,C*];
 A61K0031-20 [I,A]; A61K0031-21 [I,C*]; A61K0031-23 [I,A];
 A61K0031-231 [I,A]; C11B0003-00 [I,C*]; C11B0003-10 [I,A];
 C11B0003-12 [I,A]; C11C0003-00 [I,C*]; C11C0003-02 [I,A];
 C11C0003-14 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s 14 and (tablet or capsule)
 L5 34 L4 AND (TABLET OR CAPSULE)

=> d 20-30

L5 ANSWER 20 OF 34 USPATFULL on STN
 AN 2002:266471 USPATFULL
 TI **Bioactive conjugated linoleic acid**
 glycerides and method of use
 IN Bonsignore, Patrick V., UNITED STATES
 Gurin, Michael H., UNITED STATES
 PI US 2002147356 A1 20021010
 US 6608222 B2 20030819
 AI US 2001-1413 A1 20011121 (10)
 PRAI US 2000-252382P 20001121 (60)
 US 2000-250359P 20001201 (60)
 US 2000-254317P 20001211 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 1346
 INCL INCLM: 554/121.000
 NCL NCLM: 554/126.000; 554/121.000
 NCLS: 424/442.000; 424/451.000; 426/807.000
 IC [7]
 ICM C11D001-28
 IPCI C11D0001-28 [ICM,7]; C11D0001-02 [ICM,7,C*]
 IPCI-2 C11C0003-14 [ICM,7]; C11C0003-00 [ICM,7,C*]
 IPCR A23K0001-16 [I,A]; A23K0001-16 [I,C*]; A23L0001-30 [I,A];
 A23L0001-30 [I,C*]; A23L0002-02 [I,A]; A23L0002-02 [I,C*];
 A23L0002-52 [I,A]; A23L0002-52 [I,C*]; C11C0003-00 [I,C*];

C11C0003-02 [I,A]; C11C0003-14 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 21 OF 34 USPATFULL on STN
AN 2002:217238 USPATFULL
TI **Conjugated linoleic acid** in treatment and
prophylaxis of diabetes
IN Remmereit, Jan, Volda, NORWAY
Wadstein, Jan, Oslo, NORWAY
Klaveness, Jo, Oslo, NORWAY
PA Natural Corporation, Sandvira, NORWAY (non-U.S. corporation)
PI US 6440931 B1 20020827
AI US 2000-510059 20000222 (9)
PRAI US 1999-121232P 19990223 (60)
DT Utility
FS GRANTED
LN.CNT 783
INCL INCLM: 514/003.000
INCLS: 514/003.000; 514/002.000; 514/560.000; 514/549.000; 514/558.000;
426/630.000; 426/002.000; 426/807.000
NCL NCLM: 514/003.000
NCLS: 426/002.000; 426/630.000; 426/807.000; 514/002.000; 514/549.000;
514/558.000; 514/560.000
IC [7]
ICM A61K038-28
IPCI A61K0038-28 [ICM,7]
IPCR A23L0001-30 [I,A]; A23L0001-30 [I,C*]; A61K0031-155 [I,A];
A61K0031-155 [I,C*]; A61K0031-185 [I,C*]; A61K0031-201 [I,A];
A61K0031-64 [I,A]; A61K0031-64 [I,C*]; A61K0031-702 [I,A];
A61K0031-702 [I,C*]; A61K0038-28 [I,A]; A61K0038-28 [I,C*]
EXF 514/2; 514/3; 514/560; 514/549; 514/558; 426/630; 426/2; 426/807
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 22 OF 34 USPATFULL on STN
AN 2002:201689 USPATFULL
TI Dietary supplement containing glycerol ester of **conjugated**
linoleic acid and rosemary extract containing carnosic
acid
IN Krumhar, Kim Carleton, Carlsbad, CA, United States
PA Metagenics, Inc., San Clemente, CA, United States (U.S. corporation)
PI US 6432453 B1 20020813
AI US 2001-775299 20010201 (9)
PRAI US 2000-228249P 20000826 (60)
DT Utility
FS GRANTED
LN.CNT 409
INCL INCLM: 424/725.000
INCLS: 424/439.000
NCL NCLM: 424/725.000
NCLS: 424/439.000
IC [7]
ICM A61K047-08
ICS A61K035-78
IPCI A61K0047-08 [ICM,7]; A61K0035-78 [ICS,7]
IPCR A23L0001-30 [I,A]; A23L0001-30 [I,C*]
EXF 514/560; 514/909; 424/725; 424/439
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 23 OF 34 USPATFULL on STN
AN 2002:185364 USPATFULL
TI **Conjugated linoleic acid** compositions
IN Fimreite, Duane, Chicago, IL, UNITED STATES
Saebo, Asgeir, Eidsnes, NORWAY
PA Natual, Sandvika, NORWAY (U.S. corporation)

PI US 2002098274 A1 20020725
 US 6524527 B2 20030225
 AI US 2001-961522 A1 20010924 (9)
 RLI Continuation-in-part of Ser. No. US 1998-132593, filed on 11 Aug 1998,
 PENDING Continuation-in-part of Ser. No. US 1999-270940, filed on 17 Mar
 1999, PENDING Continuation-in-part of Ser. No. US 1998-42767, filed on
 17 Mar 1998, PATENTED Continuation-in-part of Ser. No. US 1998-42538,
 filed on 17 Mar 1998, ABANDONED
 DT Utility
 FS APPLICATION
 LN.CNT 1960
 INCL INCLM: 426/601.000
 INCLS: 424/439.000
 NCL NCLM: 426/648.000; 426/601.000
 NCLS: 554/126.000; 424/439.000
 IC [7]
 ICM A23D007-00
 ICS A23D009-00
 IPCI A23D0007-00 [ICM,7]; A23D0009-00 [ICS,7]
 IPCI-2 A23L0001-30 [ICM,7]
 IPCR A23L0001-30 [I,A]; A23L0001-30 [I,C*]; A61K0031-185 [I,C*];
 A61K0031-201 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 24 OF 34 USPATFULL on STN
 AN 2002:157826 USPATFULL
 TI Isomer enriched **conjugated linoleic acid**
 compositions
 IN Jerome, Daria, Owatonna, MN, UNITED STATES
 Skarie, Carl, Detroit Lakes, MN, UNITED STATES
 PI US 2002082436 A1 20020627
 US 6696584 B2 20040224
 AI US 2001-23598 A1 20011218 (10)
 RLI Continuation of Ser. No. US 2001-789583, filed on 22 Feb 2001, PENDING
 Continuation of Ser. No. US 1999-438101, filed on 10 Nov 1999, PATENTED
 Continuation of Ser. No. US 1998-72422, filed on 4 May 1998, PATENTED
 DT Utility
 FS APPLICATION
 LN.CNT 577
 INCL INCLM: 554/221.000
 NCL NCLM: 554/224.000; 554/221.000
 NCLS: 424/451.000; 424/648.000; 424/807.000; 554/223.000; 554/227.000
 IC [7]
 ICM C11B001-00
 ICS C07C053-00; C07C057-00
 IPCI C11B0001-00 [ICM,7]; C07C0053-00 [ICS,7]; C07C0057-00 [ICS,7]
 IPCI-2 C07C0057-00 [ICM,7]
 IPCR A23K0001-16 [I,A]; A23K0001-16 [I,C*]; A23L0001-30 [I,A];
 A23L0001-30 [I,C*]; A61K0031-185 [I,C*]; A61K0031-202 [I,A];
 C11B0003-00 [I,A]; C11B0003-00 [I,C*]; C11C0001-00 [I,C*];
 C11C0001-02 [I,A]; C11C0003-00 [I,C*]; C11C0003-02 [I,A];
 C11C0003-10 [I,A]; C11C0003-14 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 25 OF 34 USPATFULL on STN
 AN 2002:152815 USPATFULL
 TI **Conjugated linoleic acid** compositions and
 methods of making same
 IN Saebo, Asgeir, Oersta, NORWAY
 Skarie, Carl, Detroit Lakes, MN, United States
 Jerome, Daria, Owatonna, MN, United States
 Haroldsson, Gudmundur, Reykjavik, ICELAND
 PA Conlinco, Inc., Detroit Lakes, MN, United States (U.S. corporation)
 PI US 6410761 B1 20020625

L5 ANSWER 19 OF 34 USPATFULL on STN
 TI **Conjugated linoleic acid** compositions and methods of making same
 IN Saebo, Asgeir, Oersta, NORWAY
 Skarie, Carl, Detroit Lakes, MN, UNITED STATES
 Jerome, Daria, Owatonna, MN, UNITED STATES
 Haroldsson, Gudmunder, Reykjavik, ICELAND
 PI US 2002169332 A1 20021114
 US 6610868 B2 20030826
 PI US 2002169332 A1 20021114
 US 6610868 B2 20030826
 AB Novel compositions containing **conjugated linoleic acids** are efficacious as animal feed additives and human dietary supplements. Linoleic acid is converted to its conjugated forms in which the resulting composition is low in certain unusual isomers compared to conventional conjugated linoleic products.

L5 ANSWER 20 OF 34 USPATFULL on STN
 TI Bioactive **conjugated linoleic acid** glycerides and method of use
 IN Bonsignore, Patrick V., UNITED STATES
 Gurin, Michael H., UNITED STATES
 PI US 2002147356 A1 20021010
 US 6608222 B2 20030819
 PI US 2002147356 A1 20021010
 US 6608222 B2 20030819
 AB A composition and method for supplementing feed, nutrition and diet systems with bioactive glycerides of **conjugated linoleic acid** comprised of a synergistic blend of conjugated linoleic bioactive isomers acid in mono-, di-, and/or triglyceride form. The composition comprises (A) bioactive glycerides of **conjugated linoleic acid** comprised of a synergistic blend of conjugated linoleic bioactive isomers acid in mono-, di- and/or triglyceride form, (B) a carrier medium, and (C) a delivery system as a dietary supplement. The composition provides an effective increase in nutritional, therapeutic, and pharmacological properties in nutrition and diet systems.

L5 ANSWER 21 OF 34 USPATFULL on STN
 TI **Conjugated linoleic acid** in treatment and prophylaxis of diabetes
 IN Remmereit, Jan, Volda, NORWAY
 Wadstein, Jan, Oslo, NORWAY
 Klaveness, Jo, Oslo, NORWAY
 PI US 6440931 B1 20020827
 PI US 6440931 B1 20020827
 AB This invention provides method of treatment and prophylaxis of both insulin (Type I) and non-insulin dependent (type II) diabetes mellitus, by administration of **conjugated linoleic acid** (CLA) in the form of pure isomers, selected isomer mixtures or non-selected isomer mixtures. The **conjugated linoleic acids** may be administered alone, or in combination with other diabetes therapeutic regimes.

L5 ANSWER 22 OF 34 USPATFULL on STN
 TI Dietary supplement containing glycerol ester of **conjugated linoleic acid** and rosemary extract containing carnosic acid
 IN Krumhar, Kim Carleton, Carlsbad, CA, United States
 PI US 6432453 B1 20020813
 PI US 6432453 B1 20020813
 AB A composition containing a stabilized form of **conjugated linoleic acid** is described. The **conjugated**

AI US 1999-270940 19990317 (9)
 RLI Continuation-in-part of Ser. No. US 1998-132593, filed on 11 Aug 1998
 Continuation-in-part of Ser. No. US 1998-160416, filed on 25 Sep 1998
 Continuation-in-part of Ser. No. US 1998-42538, filed on 17 Mar 1998,
 now abandoned Continuation-in-part of Ser. No. US 1998-42767, filed on
 17 Mar 1998, now patented, Pat. No. US 6015833
 DT Utility
 FS GRANTED
 LN.CNT 1333
 INCL INCLM: 554/126.000
 INCLS: 554/167.000; 554/168.000; 554/173.000
 NCL NCLM: 554/126.000
 NCLS: 554/167.000; 554/168.000; 554/173.000
 IC [7]
 ICM C11C003-00
 IPCI C11C0003-00 [ICM,7]
 IPCR A23L0001-30 [I,A]; A23L0001-30 [I,C*]; A61K0031-185 [I,C*];
 A61K0031-201 [I,A]; A61K0047-48 [I,A]; A61K0047-48 [I,C*]
 EXF 554/126; 554/156; 554/157; 554/173
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 26 OF 34 USPATFULL on STN
 AN 2002:55070 USPATFULL
 TI Methods of using isomer enriched **conjugated linoleic**
acid compositions
 IN Saebo, Asgeir, Oersta, NORWAY
 Skarie, Carl, Detroit Lakes, MN, UNITED STATES
 Jerome, Daria, Owatonna, MN, UNITED STATES
 PI US 2002032233 A1 20020314
 US 7094420 B2 20060822
 AI US 2001-949458 A1 20010907 (9)
 RLI Continuation of Ser. No. US 1998-72421, filed on 4 May 1998, GRANTED,
 Pat. No. US 6214372 Continuation-in-part of Ser. No. US 1998-72422,
 filed on 4 May 1998, GRANTED, Pat. No. US 6060514 Continuation-in-part
 of Ser. No. US 1999-271021, filed on 17 Mar 1999, PENDING
 DT Utility
 FS APPLICATION
 LN.CNT 929
 INCL INCLM: 514/549.000
 INCLS: 514/560.000
 NCL NCLM: 424/439.000
 NCLS: 424/400.000
 IC [7]
 ICM A61K031-201
 ICS A61K031-22
 IPCI A61K0031-201 [ICM,7]; A61K0031-185 [ICM,7,C*]; A61K0031-22
 [ICS,7]; A61K0031-21 [ICS,7,C*]
 IPCI-2 A61K0047-00 [I,A]; A61K0009-00 [I,A]
 IPCR A23K0001-16 [I,A]; A23K0001-16 [I,C*]; A23L0001-30 [I,A];
 A23L0001-30 [I,C*]; C11B0003-00 [I,A]; C11B0003-00 [I,C*];
 C11C0001-00 [I,C*]; C11C0001-02 [I,A]; C11C0003-00 [I,C*];
 C11C0003-02 [I,A]; C11C0003-10 [I,A]; C11C0003-14 [I,A]
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

linoleic acid is reacted with glycerol to form an ester, which is much more resistant to oxidation than the acid form of the **conjugated linoleic acid**. The composition can additionally contain antioxidants, such as rosemary leaf extract, tocopherols, chelating agents, ascorbic acid, the like. The composition can also contain a fatty acid and/or glycerol ingredient. A method for supplementing an individual's diet is also described.

L5 ANSWER 23 OF 34 USPATFULL on STN
TI **Conjugated linoleic acid** compositions
IN Fimreite, Duane, Chicago, IL, UNITED STATES
Saebo, Asgeir, Eidsnes, NORWAY
PI US 2002098274 A1 20020725
US 6524527 B2 20030225
PI US 2002098274 A1 20020725
US 6524527 B2 20030225
AB Novel compositions containing **conjugated linoleic acids** are efficacious as animal feed additives and human dietary supplements. Linoleic acid is converted to its conjugated forms in which the resulting composition is low in certain unusual isomers compared to conventional conjugated linoleic products. In addition, the inventions provides compositions that are prepared according to a novel method that controls oxidation of CLA into volatile organic compounds as well as containing metal oxidant chelators to control oxidation during storage.

L5 ANSWER 24 OF 34 USPATFULL on STN
TI Isomer enriched **conjugated linoleic acid** compositions
IN Jerome, Daria, Owatonna, MN, UNITED STATES
Skarie, Carl, Detroit Lakes, MN, UNITED STATES
PI US 2002082436 A1 20020627
US 6696584 B2 20040224
PI US 2002082436 A1 20020627
US 6696584 B2 20040224
AB Compositions and methods of using **conjugated linoleic acid** preparations enriched for the t10,c12 and c9,t11 isomers are disclosed. It is found that preparations of **conjugated linoleic acid** containing a ratio of t10,c12 to c9,t11 of about greater than 1.2:1 are desirable for a wide variety of nutritional, therapeutic and pharmacologic uses.

L5 ANSWER 25 OF 34 USPATFULL on STN
TI **Conjugated linoleic acid** compositions and methods of making same
IN Saebo, Asgeir, Oersta, NORWAY
Skarie, Carl, Detroit Lakes, MN, United States
Jerome, Daria, Owatonna, MN, United States
Haroldsson, Gudmundur, Reykjavik, ICELAND
PI US 6410761 B1 20020625
PI US 6410761 B1 20020625
AB Novel compositions containing **conjugated linoleic acids** are efficacious as animal feed additives and human dietary supplements. Linoleic acid is converted to its conjugated forms in which the resulting composition is low in certain unusual isomers compared to conventional conjugated linoleic products.

L5 ANSWER 26 OF 34 USPATFULL on STN
TI Methods of using isomer enriched **conjugated linoleic acid** compositions
IN Saebo, Asgeir, Oersta, NORWAY
Skarie, Carl, Detroit Lakes, MN, UNITED STATES
Jerome, Daria, Owatonna, MN, UNITED STATES
PI US 2002032233 A1 20020314
US 7094420 B2 20060822

PI US 2002032233 A1 20020314
US 7094420 B2 20060822

AB Compositions and methods of using **conjugated linoleic acid** preparations enriched for the t10,c12 and c9,t11 isomers are disclosed. It is found that preparations of **conjugated linoleic acid** containing a ratio of t10,c12 to c9,t11 of about greater than 1.2:1 are desirable for a wide variety of nutritional, therapeutic and pharmacologic uses.

L5 ANSWER 27 OF 34 USPATFULL on STN

TI Agent for increasing brown fat, comprising **conjugated linoleic acid** as active ingredient

IN Sugano, Michihiro, Kumamoto-shi, JAPAN
Sakuno, Masanobu, Miyazaki-shi, JAPAN
Koba, Kazunori, Nagasaki-shi, JAPAN
Okuyama, Hitoshi, Tokyo-To, JAPAN
Kasai, Masaaki, Nagoya-shi, JAPAN
Iwata, Toshio, Tokyo-To, JAPAN

PI US 2002015771 A1 20020207
US 6451336 B2 20020917

PI US 2002015771 A1 20020207
US 6451336 B2 20020917

AB There is provided an agent for increasing brown fat, comprising a **conjugated linoleic acid** as an active ingredient.

L5 ANSWER 28 OF 34 USPATFULL on STN

TI **Conjugated linoleic acid** powder

IN Fimreite, Duane, Chicago, IL, UNITED STATES

PI US 2002013365 A1 20020131
US 6756405 B2 20040629

PI US 2002013365 A1 20020131
US 6756405 B2 20040629

AB A powder containing a high amount of **conjugated linoleic acid** or other oil is provided. The powder contains either triglycerides containing CLA, free fatty acids of CLA, or alkylesters of CLA, or another desired oil. The powder is free flowing and has good organoleptic properties. The powder may be used as a dietary supplement or combined with foodstuffs to form a food product suitable for consumption by animals or humans.

L5 ANSWER 29 OF 34 USPATFULL on STN

TI Isomer enriched **conjugated linoleic acid** compositions

IN Saebo, Asgeir, Oersta, Norway
Skarie, Carl, Detroit Lakes, MN, United States
Jerome, Daria, Owatonna, MN, United States

PI US 2001025113 A1 20010927
US 6333353 B2 20011225

PI US 2001025113 A1 20010927
US 6333353 B2 20011225

AB Compositions and methods of using **conjugated linoleic acid** preparations enriched for the t10,c12 and c9,t11 isomers are disclosed. It is found that preparations of **conjugated linoleic acid** containing a ratio of t10,c12 to c9,t11 of about greater than 1.2:1 are desirable for a wide variety of nutritional, therapeutic and pharmacologic uses.

L5 ANSWER 30 OF 34 USPATFULL on STN

TI Isomer enriched **conjugated linoleic acid** compositions

IN Jerome, Daria, Owatonna, MN, United States
Skarie, Carl, Detroit Lakes, MN, United States

PI US 6242621 B1 20010605

PI US 6242621 B1 20010605
 AB Compositions and methods of using **conjugated linoleic acid** preparations enriched for the t10,c12 and c9,t11 isomers are disclosed. It is found that preparations of **conjugated linoleic acid** containing a ratio of t10,c12 to c9,t11 of about greater than 1.2:1 are desirable for a wide variety of nutritional, therapeutic and pharmacologic uses.

L5 ANSWER 31 OF 34 USPTAFULL on STN
 TI Isomer enriched **conjugated linoleic acid** compositions
 IN Saebo, Asgeir, Oersta, Norway
 Skarie, Carl, Detroit Lakes, MN, United States
 Jerome, Daria, Owatonna, MN, United States
 PI US 6225486 B1 20010501
 PI US 6225486 B1 20010501
 AB Compositions and methods of using **conjugated linoleic acid** preparations enriched for the t10,c12 and c9,t11 isomers are disclosed. It is found that preparations of **conjugated linoleic acid** containing a ratio of t10,c12 to c9,t11 of about greater than 1.2:1 are desirable for a wide variety of nutritional, therapeutic and phatmacologic uses.

L5 ANSWER 32 OF 34 USPTAFULL on STN
 TI Method of using isomer enriched **conjugated linoleic acid** compositions
 IN Jerome, Daria, Detroit Lakes, MN, United States
 Skarie, Carl, Detroit Lakes, MN, United States
 PI US 6214372 B1 20010410
 PI US 6214372 B1 20010410
 AB Compositions and methods of using **conjugated linoleic acid** preparations enriched for the t10,c12 and c9,t11 isomers are disclosed. It is found that preparations of **conjugated linoleic acid** containing a ratio of t10,c12 to c9,t11 of about greater than 1.2:1 are desirable for a wide variety of nutritional, therapeutic and pharmacologic uses.

L5 ANSWER 33 OF 34 USPTAFULL on STN
 TI Use of **conjugated linoleic acids**
 IN Vanderhoek, Jack Y., Bethesda, MD, United States
 PI US 6077525 20000620
 PI US 6077525 20000620
 AB The use of **conjugated linoleic acid** to inhibit cyclooxygenase-catalyzed conversion of arachidonic acid, thromboxane formation and platelet aggregation.

L5 ANSWER 34 OF 34 USPTAFULL on STN
 TI Isomer enriched **conjugated linoleic acid** compositions
 IN Jerome, Daria, Detroit Lakes, MN, United States
 Skarie, Carl, Detroit Lakes, MN, United States
 PI US 6060514 20000509
 PI US 6060514 20000509
 AB Compositions and methods of using **conjugated linoleic acid** preparations enriched for the t10,c12 and c9,t11 isomers are disclosed. It is found that preparations of **conjugated linoleic acid** containing a ratio of t10,c12 to c9,t11 of about greater than 1.2:1 are desirable for a wide variety of nutritional, therapeutic and pharmacologic uses.